Michael DeMane

Michael DeMane is Executive Chairman of Nevro, a Silicon Valley-based leader in the medical device field. Michael led the company as CEO from March, 2011 until June, 2016, from scrappy start-up with negligible revenue to a leading global player in the spinal cord stimulation market. With an emphasis on the mechanics and culture of building the business, under his leadership the company raised two venture funding rounds totaling $106M, completed a $145M IPO (upsized and priced above the range), and subsequently initiated a public follow-on offering, again upsized to $260M.

An engineer by training, Mr. DeMane has established a consistent record of success leading both large and mid-size global med-tech organizations. Over the past 35 years, he has held executive leadership roles in the US, Europe and Australasia.

Prior to Nevro, Michael held a variety of positions at Medtronic, Inc., including: Chief Operating Officer, Sr. VP and President Europe, Canada, Latin America and Emerging Markets, and Sr. VP and President Spinal, ENT, and Navigation. In each of these roles he served on Medtronic’s Executive Committee.

Before joining Medtronic, Mr. DeMane served as Managing Director, Australasia for Smith & Nephew Pty. Ltd.

Michael has served as Senior Advisor to Thomas McNerney & Partners, and Oak Hill Capital. In addition he is on the Board of Directors of several firms in the medtech space including Cardionomic, Inc., Rotation Medical and SafeOrthopaedics.

Mr. DeMane has completed the Advanced Management Program at INSEAD in Fontainebleau, France and holds an M.S. in Bioengineering from Clemson University and a B.S in Chemistry from St. Lawrence University in Canton, New York.